West Paces Advisors’s 10x Genomics TXG Stock Holding History

West Paces Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-455	Closed	-$13K	–	561
2022 Q3	$13K	Hold	455	–	–	﹤0.01%	322
2022 Q2	$20.6K	Hold	455	–	–	0.01%	298
2022 Q1	$34.6K	Hold	455	–	–	0.01%	256
2021 Q4	$67.8K	Hold	455	–	–	0.02%	209
2021 Q3	$66.2K	Hold	455	–	–	0.02%	193
2021 Q2	$89.1K	Hold	455	–	–	0.03%	158
2021 Q1	$82.4K	Hold	455	–	–	0.03%	155
2020 Q4	$64.4K	Hold	455	–	–	0.03%	166
2020 Q3	$56.7K	Hold	455	–	–	0.03%	166
2020 Q2	$40.6K	Hold	455	–	–	0.02%	188
2020 Q1	$28.4K	Hold	455	–	–	0.02%	211
2019 Q4	$34.7K	Hold	455	–	–	0.02%	221
2019 Q3	$22.9K	Buy	+455	New	+$25.2K	0.01%	249

Other funds holding TXG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SIM

SRS Investment Management New York $10.8B AUM 34.05% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

West Paces Advisors's TXG Position: Q4 2022 in Review

West Paces Advisors sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 455 shares — an estimated $13K sold.

West Paces Advisors first reported a position in TXG in Q3 2019 and held it in 13 quarters. The position peaked at $89.1K in Q2 2021. 266 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

West Paces Advisors reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
West Paces Advisors sold 455 10x Genomics shares in Q4 2022, an estimated $13K.
West Paces Advisors first reported a position in 10x Genomics in Q3 2019 and held it in 13 quarters.
West Paces Advisors's 10x Genomics position peaked at $89.1K in Q2 2021.
266 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on West Paces Advisors's 13F filing for Q4 2022, filed 18 Dec 2023.